bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figure 1 from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Authors: Leuci Valeria , Donini Chiara , Grignani Giovanni , Rotolo Ramona , Mesiano Giulia , Fiorino Erika , Gammaitoni Loretta , D'Ambrosio Lorenzo , Merlini Alessandra , Landoni Elisa , Medico Enzo , Capellero Sonia , Giraudo Lidia , Cattaneo Giulia , Iaia Ilenia , Pignochino Ymera , Basiricò Marco , Vigna Elisa , Pisacane Alberto , Fagioli Franca , Ferrone Soldano , Aglietta Massimo , Dotti Gianpietro , Sangiolo Dario
Published: April 2023

Phenotypic characterization of CSPG4-CAR.CIK
Suppl. Video 5 from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Authors: Leuci Valeria , Donini Chiara , Grignani Giovanni , Rotolo Ramona , Mesiano Giulia , Fiorino Erika , Gammaitoni Loretta , D'Ambrosio Lorenzo , Merlini Alessandra , Landoni Elisa , Medico Enzo , Capellero Sonia , Giraudo Lidia , Cattaneo Giulia , Iaia Ilenia , Pignochino Ymera , Basiricò Marco , Vigna Elisa , Pisacane Alberto , Fagioli Franca , Ferrone Soldano , Aglietta Massimo , Dotti Gianpietro , Sangiolo Dario
Published: April 2023

CSPG4-CAR.CIK vs S5 - 3D-RECONSTRUCTION
Figure S5 from A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer
Authors: Prat Aleix , Tsai Yi-Hsuan , Pascual Tomás , Paré Laia , Adamo Barbara , Vidal Maria , Brasó-Maristany Fara , Galván Patricia , Brase Jan Christoph , Rodrik-Outmezguine Vanessa , Johnston Stephen , Ciruelos Eva , Parker Joel S.
Published: April 2023

Survival outcomes based on the PAM50MET score in the BOLERO-2 trial according to non-visceral versus visceral disease. (A) Progression-free survival of PAM50MET in patients with non-visceral disease. (B) Overall survival of PAM50MET in patients with non-visceral disease. (C) Progression-free survival of PAM50MET in patients with visceral disease. (D) Overall survival of PAM50MET in patients with visceral disease.
Suppl. Video 3 from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Authors: Leuci Valeria , Donini Chiara , Grignani Giovanni , Rotolo Ramona , Mesiano Giulia , Fiorino Erika , Gammaitoni Loretta , D'Ambrosio Lorenzo , Merlini Alessandra , Landoni Elisa , Medico Enzo , Capellero Sonia , Giraudo Lidia , Cattaneo Giulia , Iaia Ilenia , Pignochino Ymera , Basiricò Marco , Vigna Elisa , Pisacane Alberto , Fagioli Franca , Ferrone Soldano , Aglietta Massimo , Dotti Gianpietro , Sangiolo Dario
Published: April 2023

CSPG4-CAR.CIK vs S5 - INFILTRATION
Suppl. Video 2 from CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes
Authors: Leuci Valeria , Donini Chiara , Grignani Giovanni , Rotolo Ramona , Mesiano Giulia , Fiorino Erika , Gammaitoni Loretta , D'Ambrosio Lorenzo , Merlini Alessandra , Landoni Elisa , Medico Enzo , Capellero Sonia , Giraudo Lidia , Cattaneo Giulia , Iaia Ilenia , Pignochino Ymera , Basiricò Marco , Vigna Elisa , Pisacane Alberto , Fagioli Franca , Ferrone Soldano , Aglietta Massimo , Dotti Gianpietro , Sangiolo Dario
Published: April 2023

NTD.CIK vs S5 -CYTOTOXICITY
Figure S1 from A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor–positive HER2-negative Breast Cancer
Authors: Prat Aleix , Tsai Yi-Hsuan , Pascual Tomás , Paré Laia , Adamo Barbara , Vidal Maria , Brasó-Maristany Fara , Galván Patricia , Brase Jan Christoph , Rodrik-Outmezguine Vanessa , Johnston Stephen , Ciruelos Eva , Parker Joel S.
Published: April 2023

C-index analyses of the different prognostic models built and tested in the EGF30008 trial. PAM50, Prediction Analysis of Microarray 50.
Figure S4 from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Authors: Crosby Erika J. , Acharya Chaitanya R. , Haddad Anthony-Fayez , Rabiola Christopher A. , Lei Gangjun , Wei Jun-Ping , Yang Xiao-Yi , Wang Tao , Liu Cong-Xiao , Wagner Kay U. , Muller William J. , Chodosh Lewis A. , Broadwater Gloria , Hyslop Terry , Shepherd Jonathan H. , Hollern Daniel P. , He Xiaping , Perou Charles M. , Chai Shengjie , Ashby Benjamin K. , Vincent Benjamin G. , Snyder Joshua C. , Force Jeremy , Morse Michael A. , Lyerly Herbert K. , Hartman Zachary C.
Published: April 2023

Supplementary Figure 4
Supplementary Data from Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials
Authors: Kates Max , Matoso Andres , Choi Woonyoung , Baras Alexander S. , Daniels Marcus J. , Lombardo Kara , Brant Aaron , Mikkilineni Nina , McConkey David J. , Kamat Ashish M. , Svatek Robert S. , Porten Sima P. , Meeks Joshua J. , Lerner Seth P. , Dinney Colin P. , Black Peter C. , McKiernan James M. , Anderson Chris , Drake Charles G. , Bivalacqua Trinity J.
Published: April 2023

Supplementary Figure 1
Figure S3 from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Authors: Crosby Erika J. , Acharya Chaitanya R. , Haddad Anthony-Fayez , Rabiola Christopher A. , Lei Gangjun , Wei Jun-Ping , Yang Xiao-Yi , Wang Tao , Liu Cong-Xiao , Wagner Kay U. , Muller William J. , Chodosh Lewis A. , Broadwater Gloria , Hyslop Terry , Shepherd Jonathan H. , Hollern Daniel P. , He Xiaping , Perou Charles M. , Chai Shengjie , Ashby Benjamin K. , Vincent Benjamin G. , Snyder Joshua C. , Force Jeremy , Morse Michael A. , Lyerly Herbert K. , Hartman Zachary C.
Published: April 2023

Supplementary Figure 3
Figure S2 from Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Authors: Crosby Erika J. , Acharya Chaitanya R. , Haddad Anthony-Fayez , Rabiola Christopher A. , Lei Gangjun , Wei Jun-Ping , Yang Xiao-Yi , Wang Tao , Liu Cong-Xiao , Wagner Kay U. , Muller William J. , Chodosh Lewis A. , Broadwater Gloria , Hyslop Terry , Shepherd Jonathan H. , Hollern Daniel P. , He Xiaping , Perou Charles M. , Chai Shengjie , Ashby Benjamin K. , Vincent Benjamin G. , Snyder Joshua C. , Force Jeremy , Morse Michael A. , Lyerly Herbert K. , Hartman Zachary C.
Published: April 2023

Supplementary Figure 2
Supplementary table 2 from Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma
Authors: Lozano Ester , Mena Mari-Pau , Díaz Tania , Martin-Antonio Beatriz , León Sheila , Rodríguez-Lobato Luis-Gerardo , Oliver-Caldés Aina , Cibeira Maria Teresa , Bladé Joan , Prat Aleix , Rosiñol Laura , Fernández de Larrea Carlos
Published: April 2023

Supplementary Table S2. Gene expression analysis of CD138- BM cells from 12 patients with MM by using nanostring technology.
figure S9 from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Authors: Marusak Charles , Thakur Varsha , Li Yuan , Freitas Juliano T. , Zmina Patrick M. , Thakur Vijay S. , Chang Mayland , Gao Ming , Tan Jiufeng , Xiao Min , Lu Yiling , Mills Gordon B. , Flaherty Keith , Frederick Dennie T. , Miao Benchun , Sullivan Ryan J. , Moll Tabea , Boland Genevieve M. , Herlyn Meenhard , Zhang Gao , Bedogni Barbara
Published: April 2023

MMP2
Supplementary fig 2 from Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma
Authors: Lozano Ester , Mena Mari-Pau , Díaz Tania , Martin-Antonio Beatriz , León Sheila , Rodríguez-Lobato Luis-Gerardo , Oliver-Caldés Aina , Cibeira Maria Teresa , Bladé Joan , Prat Aleix , Rosiñol Laura , Fernández de Larrea Carlos
Published: April 2023

Supplementary Figure S2. Frequencies of CD3+CD4+CD127lowCD25high T cells in the BM. (A) Representative dot plots of CD127lowCD25high T cells gating on CD3+CD4+ in the BM of responder and non-responder patient to TIGIT blockade (B) Summarized data showing that responders had a significant lower percentage of CD3+CD4+CD127lowCD25high T cells than non-responders (n=5 vs. n=7 Mann Whitney test p=0.017).
Supplementary fig 1 from Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma
Authors: Lozano Ester , Mena Mari-Pau , Díaz Tania , Martin-Antonio Beatriz , León Sheila , Rodríguez-Lobato Luis-Gerardo , Oliver-Caldés Aina , Cibeira Maria Teresa , Bladé Joan , Prat Aleix , Rosiñol Laura , Fernández de Larrea Carlos
Published: April 2023

Supplementary Figure S1. Frequencies of TIGIT+ BM cells in patients with MM at different stages of disease. (A) Percentage of TIGIT+ CD4+ T cells, TIGIT+ CD8+ T cells and NK cells as a frequency of total BM cells. Kruskal Wallis test followed by Dunn's multiple comparison tests *p<0.05. (B) Total percentage of BM TIGIT+ cells at different stages of disease. (C) Positive correlation of frequency of TIGIT+ CD4+ T cells and TIGIT+ CD8+ T cells in 64 patients with MM (SMM n=15, NDMM n=24, RRMM n=25). Spearman correlation ***p<0.0001.
figure S4 from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Authors: Marusak Charles , Thakur Varsha , Li Yuan , Freitas Juliano T. , Zmina Patrick M. , Thakur Vijay S. , Chang Mayland , Gao Ming , Tan Jiufeng , Xiao Min , Lu Yiling , Mills Gordon B. , Flaherty Keith , Frederick Dennie T. , Miao Benchun , Sullivan Ryan J. , Moll Tabea , Boland Genevieve M. , Herlyn Meenhard , Zhang Gao , Bedogni Barbara
Published: April 2023

Cooperativity indexes
Supplementary Methods from Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma
Authors: Lozano Ester , Mena Mari-Pau , Díaz Tania , Martin-Antonio Beatriz , León Sheila , Rodríguez-Lobato Luis-Gerardo , Oliver-Caldés Aina , Cibeira Maria Teresa , Bladé Joan , Prat Aleix , Rosiñol Laura , Fernández de Larrea Carlos
Published: April 2023

Supplementary Methods
figure S13 from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Authors: Marusak Charles , Thakur Varsha , Li Yuan , Freitas Juliano T. , Zmina Patrick M. , Thakur Vijay S. , Chang Mayland , Gao Ming , Tan Jiufeng , Xiao Min , Lu Yiling , Mills Gordon B. , Flaherty Keith , Frederick Dennie T. , Miao Benchun , Sullivan Ryan J. , Moll Tabea , Boland Genevieve M. , Herlyn Meenhard , Zhang Gao , Bedogni Barbara
Published: April 2023

TGFbeta inhibitor
Figure S8 from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Authors: Marusak Charles , Thakur Varsha , Li Yuan , Freitas Juliano T. , Zmina Patrick M. , Thakur Vijay S. , Chang Mayland , Gao Ming , Tan Jiufeng , Xiao Min , Lu Yiling , Mills Gordon B. , Flaherty Keith , Frederick Dennie T. , Miao Benchun , Sullivan Ryan J. , Moll Tabea , Boland Genevieve M. , Herlyn Meenhard , Zhang Gao , Bedogni Barbara
Published: April 2023

MT1-MMP overexpression
Supplementary Data from Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell–Level PI3K Pathway Activation
Authors: Stopsack Konrad H. , Huang Ying , Tyekucheva Svitlana , Gerke Travis A. , Bango Clyde , Elfandy Habiba , Bowden Michaela , Penney Kathryn L. , Roberts Thomas M. , Parmigiani Giovanni , Kantoff Philip W. , Mucci Lorelei A. , Loda Massimo
Published: April 2023

All supplementary tables and figures
Figure S7 from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Authors: Marusak Charles , Thakur Varsha , Li Yuan , Freitas Juliano T. , Zmina Patrick M. , Thakur Vijay S. , Chang Mayland , Gao Ming , Tan Jiufeng , Xiao Min , Lu Yiling , Mills Gordon B. , Flaherty Keith , Frederick Dennie T. , Miao Benchun , Sullivan Ryan J. , Moll Tabea , Boland Genevieve M. , Herlyn Meenhard , Zhang Gao , Bedogni Barbara
Published: April 2023

BRAFi/MEKi resistant cells
Figure S6 from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Authors: Marusak Charles , Thakur Varsha , Li Yuan , Freitas Juliano T. , Zmina Patrick M. , Thakur Vijay S. , Chang Mayland , Gao Ming , Tan Jiufeng , Xiao Min , Lu Yiling , Mills Gordon B. , Flaherty Keith , Frederick Dennie T. , Miao Benchun , Sullivan Ryan J. , Moll Tabea , Boland Genevieve M. , Herlyn Meenhard , Zhang Gao , Bedogni Barbara
Published: April 2023

second shRNA against MT1-MMP
Figure S11 from Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma
Authors: Marusak Charles , Thakur Varsha , Li Yuan , Freitas Juliano T. , Zmina Patrick M. , Thakur Vijay S. , Chang Mayland , Gao Ming , Tan Jiufeng , Xiao Min , Lu Yiling , Mills Gordon B. , Flaherty Keith , Frederick Dennie T. , Miao Benchun , Sullivan Ryan J. , Moll Tabea , Boland Genevieve M. , Herlyn Meenhard , Zhang Gao , Bedogni Barbara
Published: April 2023

ITGB1
Supplementary Figure 1 from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
Authors: Ganci Federica , Pulito Claudio , Valsoni Sara , Sacconi Andrea , Turco Chiara , Vahabi Mahrou , Manciocco Valentina , Mazza Emilia Maria Cristina , Meens Jalna , Karamboulas Christina , Nichols Anthony C. , Covello Renato , Pellini Raul , Spriano Giuseppe , Sanguineti Giuseppe , Muti Paola , Bicciato Silvio , Ailles Laurie , Strano Sabrina , Fontemaggi Giulia , Blandino Giovanni
Published: April 2023

Supplementary Figure 1
Supplementary Data from PI3K Inhibitors Curtail MYC-Dependent Mutant p53 Gain-of-Function in Head and Neck Squamous Cell Carcinoma
Authors: Ganci Federica , Pulito Claudio , Valsoni Sara , Sacconi Andrea , Turco Chiara , Vahabi Mahrou , Manciocco Valentina , Mazza Emilia Maria Cristina , Meens Jalna , Karamboulas Christina , Nichols Anthony C. , Covello Renato , Pellini Raul , Spriano Giuseppe , Sanguineti Giuseppe , Muti Paola , Bicciato Silvio , Ailles Laurie , Strano Sabrina , Fontemaggi Giulia , Blandino Giovanni
Published: April 2023

Supplementaty tables
Table S4 from PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Authors: Guarneri Valentina , Dieci Maria Vittoria , Bisagni Giancarlo , Brandes Alba A. , Frassoldati Antonio , Cavanna Luigi , Musolino Antonino , Giotta Francesco , Rimanti Anita , Garrone Ornella , Bertone Elena , Cagossi Katia , Nanni Oriana , Piacentini Federico , Orvieto Enrico , Griguolo Gaia , Curtarello Matteo , Urso Loredana , Paré Laia , Chic Nuria , D'Amico Roberto , Prat Aleix , Conte Pierfranco
Published: April 2023

Differentially expressed genes in HER2-enriched tumors according to PIK3CA mutation.
Table S2 from PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Authors: Guarneri Valentina , Dieci Maria Vittoria , Bisagni Giancarlo , Brandes Alba A. , Frassoldati Antonio , Cavanna Luigi , Musolino Antonino , Giotta Francesco , Rimanti Anita , Garrone Ornella , Bertone Elena , Cagossi Katia , Nanni Oriana , Piacentini Federico , Orvieto Enrico , Griguolo Gaia , Curtarello Matteo , Urso Loredana , Paré Laia , Chic Nuria , D'Amico Roberto , Prat Aleix , Conte Pierfranco
Published: April 2023

Baseline characteristics of the patients included (PIK3CA cohort) or not (no-PIK3CA cohort) in the PIK3CA analysis.
Supplemental Tables 1-9 from A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
Authors: Evens Andrew M. , Hong Fangxin , Habermann Thomas M. , Advani Ranjana H. , Gascoyne Randy D. , Witzig Thomas E. , Quon Andrew , Ranheim Erik A. , Ansell Stephen M. , Cheema Puneet Singh , Dy Philip A. , O'Brien Timothy E. , Winter Jane N. , Cescon Terrence P. , Chang Julie E. , Kahl Brad S.
Published: April 2023

Supplemental Tables 1-9
Table S1 from PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
Authors: Guarneri Valentina , Dieci Maria Vittoria , Bisagni Giancarlo , Brandes Alba A. , Frassoldati Antonio , Cavanna Luigi , Musolino Antonino , Giotta Francesco , Rimanti Anita , Garrone Ornella , Bertone Elena , Cagossi Katia , Nanni Oriana , Piacentini Federico , Orvieto Enrico , Griguolo Gaia , Curtarello Matteo , Urso Loredana , Paré Laia , Chic Nuria , D'Amico Roberto , Prat Aleix , Conte Pierfranco
Published: April 2023

Complete lists of genes evaluated using the nCounter platform (plus five housekeeping genes: ACTB, MRPL19, PSMC4, RPLP0, SF3A1).
Supplementary Data Table 1 from B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade
Authors: Kim Sangwoo S. , Shen Sarek , Miyauchi Sayuri , Sanders P. Dominick , Franiak-Pietryga Ida , Mell Loren , Gutkind J. Silvio , Cohen Ezra E.W. , Califano Joseph A. , Sharabi Andrew B.
Published: April 2023

Supplementary Data Table 1
Supplementary Data from Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib
Authors: Tripathi Abhishek , Supko Jeffrey G. , Gray Kathryn P. , Melnick Zachary J. , Regan Meredith M. , Taplin Mary-Ellen , Choudhury Atish D. , Pomerantz Mark M. , Bellmunt Joaquim , Yu Channing , Sun Zijie , Srinivas Sandy , Kantoff Philip W. , Sweeney Christopher J. , Harshman Lauren C.
Published: April 2023

Supplementary materials
Supplementary Data from Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study
Authors: Zamarin Dmitriy , Hamid Omid , Nayak-Kapoor Asha , Sahebjam Solmaz , Sznol Mario , Collaku Agron , Fox Floyd E. , Marshall Margaret A. , Hong David S.
Published: April 2023

Supplementary Information
Supplementary Data from Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study
Authors: Xing Ligang , Pan Yueyin , Shi Yuankai , Shu Yongqian , Feng Jifeng , Li Wei , Cao Lejie , Wang Lifeng , Gu Wei , Song Yong , Xing Puyuan , Liu Yutao , Gao Wen , Cui Jiuwei , Hu Nana , Li Rutian , Bao Hua , Shao Yang , Yu Jinming
Published: April 2023

Supplementary material
Supplementary TableS2 from AsiDNA Is a Radiosensitizer with no Added Toxicity in Medulloblastoma Pediatric Models
Authors: Ferreira Sofia , Foray Chloe , Gatto Alberto , Larcher Magalie , Heinrich Sophie , Lupu Mihaela , Mispelter Joel , Boussin François D. , Pouponnot Célio , Dutreix Marie
Published: April 2023

Supplementary Table S2 - Significance and variation given by radiation, AsiDNA or interaction (AsiDNA with radiation) calculated by two-way ANOVA test.
Figure S2: Screening with drugs compared with DMSO control. from Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer
Authors: Cooper Alissa J. , Kobayashi Yoshihisa , Kim Dewey , Clifford Sarah E. , Kravets Sasha , Dahlberg Suzanne E. , Chambers Emily S. , Li Jiaqi , Rangachari Deepa , Nguyen Tom , Costa Daniel B. , Rabin Michael S. , Wagle Nikhil , Sholl Lynette M. , Jänne Pasi A , Oxnard Geoffrey R.
Published: April 2023

Screening with drugs targeting sunitinib related receptor tyrosine kinases (RTK) or MAPK pathway were performed in PC9TMEM87A-RASGRF1 clone 1. Relative viability compared with control (treated with DMSO) was shown. A modest inhibitory effect was seen for gilteritinib without control osimertinib, suggesting the off-target toxic effect of the drug rather than on-target inhibition.
Supplementary Figure Legends from Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial
Authors: Mei Qian , Zhang Wenying , Liu Yang , Yang Qingming , Rasko John E.J. , Nie Jing , Liu Jiejie , Li Xiang , Dong Liang , Chen Meixia , Zhang Yan , Shi Lu , Wu Huitao , Han Weidong
Published: April 2023

Figure legends of 5 supplementary figures.
FigureS2 from AsiDNA Is a Radiosensitizer with no Added Toxicity in Medulloblastoma Pediatric Models
Authors: Ferreira Sofia , Foray Chloe , Gatto Alberto , Larcher Magalie , Heinrich Sophie , Lupu Mihaela , Mispelter Joel , Boussin François D. , Pouponnot Célio , Dutreix Marie
Published: April 2023

Effect of treatments in developing models.
FigureS1 from AsiDNA Is a Radiosensitizer with no Added Toxicity in Medulloblastoma Pediatric Models
Authors: Ferreira Sofia , Foray Chloe , Gatto Alberto , Larcher Magalie , Heinrich Sophie , Lupu Mihaela , Mispelter Joel , Boussin François D. , Pouponnot Célio , Dutreix Marie
Published: April 2023

Pharmacokinetics of Cy5.5-AsiDNA after IP injection.
Figure S3 from Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial
Authors: Mei Qian , Zhang Wenying , Liu Yang , Yang Qingming , Rasko John E.J. , Nie Jing , Liu Jiejie , Li Xiang , Dong Liang , Chen Meixia , Zhang Yan , Shi Lu , Wu Huitao , Han Weidong
Published: April 2023

Time to response (TTR) and Progression-free Survival (PFS) in relation to different subgroups
Figure S2 from Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis
Authors: Indraccolo Stefano , De Salvo Gian Luca , Verza Martina , Caccese Mario , Esposito Giovanni , Piga Ilaria , Del Bianco Paola , Pizzi Marco , Gardiman Marina Paola , Eoli Marica , Rudà Roberta , Brandes Alba Ariela , Ibrahim Toni , Rizzato Simona , Lolli Ivan , Zagonel Vittorina , Lombardi Giuseppe
Published: April 2023

Immunohistochemical staining of three markers (MCT4, pAMPK and pACC) showing their expression in peri-necrotic areas of GBM samples.
Supplementary Data from Acute Statin Treatment Improves Antibody Accumulation in EGFR- and PSMA-Expressing Tumors
Authors: Pereira Patrícia M.R. , Mandleywala Komal , Ragupathi Ashwin , Lewis Jason S.
Published: April 2023

Supplementary Figures and Tables
Supplementary Data from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Authors: Dunphy Mark P.S. , Pressl Christina , Pillarsetty Nagavarakishore , Grkovski Milan , Modi Shanu , Jhaveri Komal , Norton Larry , Beattie Bradley J. , Zanzonico Pat B. , Zatorska Danuta , Taldone Tony , Ochiana Stefan O. , Uddin Mohammad M. , Burnazi Eva M. , Lyashchenko Serge K. , Hudis Clifford A. , Bromberg Jacqueline , Schöder Heiko M. , Fox Josef J. , Zhang Hanwen , Chiosis Gabriela , Lewis Jason S. , Larson Steven M.
Published: April 2023

Supplementary figures and methods
Supplementary Data from Identification of Non–Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics
Authors: Dercle Laurent , Fronheiser Matthew , Lu Lin , Du Shuyan , Hayes Wendy , Leung David K. , Roy Amit , Wilkerson Julia , Guo Pingzhen , Fojo Antonio T. , Schwartz Lawrence H. , Zhao Binsheng
Published: April 2023

Supplement
Supplemental Figure 4 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer
Authors: Dunphy Mark P.S. , Pressl Christina , Pillarsetty Nagavarakishore , Grkovski Milan , Modi Shanu , Jhaveri Komal , Norton Larry , Beattie Bradley J. , Zanzonico Pat B. , Zatorska Danuta , Taldone Tony , Ochiana Stefan O. , Uddin Mohammad M. , Burnazi Eva M. , Lyashchenko Serge K. , Hudis Clifford A. , Bromberg Jacqueline , Schöder Heiko M. , Fox Josef J. , Zhang Hanwen , Chiosis Gabriela , Lewis Jason S. , Larson Steven M.
Published: April 2023

PET detects subcentimeter PU-H71 retention by breast cancer metastases. 65-year-old female with stage IV breast cancer, off-treatment. 124I-PU-H71 PET (right), CT (left), and fusion PET/CT (middle) images show corresponding axial planes of chest, obtained 24 hours post-injection. Tracer has cleared from blood (asterisk, aorta) with sustained PU-H71 retention by biopsy-proven subcentimeter pulmonary metastasis (arrow) and left internal mammary and mediastinal nodal metastases (arrowheads).
Supplementary Table S8 from Noninvasive Detection of Urothelial Carcinoma by Cost-effective Low-coverage Whole-genome Sequencing from Urine-Exfoliated Cell DNA
Authors: Zeng Shuxiong , Ying Yidie , Xing Naidong , Wang Baiyun , Qian Ziliang , Zhou Zunlin , Zhang Zhensheng , Xu Weidong , Wang Huiqing , Dai Lihe , Gao Li , Zhou Tie , Ji Jiatao , Xu Chuanliang
Published: April 2023

Comparison between the results of UroCAD and cytology tests in training cohort.
Supplementary Table S1-6 from Noninvasive Detection of Urothelial Carcinoma by Cost-effective Low-coverage Whole-genome Sequencing from Urine-Exfoliated Cell DNA
Authors: Zeng Shuxiong , Ying Yidie , Xing Naidong , Wang Baiyun , Qian Ziliang , Zhou Zunlin , Zhang Zhensheng , Xu Weidong , Wang Huiqing , Dai Lihe , Gao Li , Zhou Tie , Ji Jiatao , Xu Chuanliang
Published: April 2023

Summary of related data of UroCAD assay.
Supplementary Fig 2 from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer
Authors: Bardia Aditya , Modi Shanu , Oliveira Mafalda , Cortes Javier , Campone Mario , Ma Brigette , Dirix Luc , Weise Amy , Hewes Becker , Diaz-Padilla Ivan , Han Yu , Deshpande Priya , Samant Tanay S. , Lorenc Karen Rodriguez , He Wei , Su Fei , Chavez-MacGregor Mariana
Published: April 2023

Supplementary Fig 2
Supplementary Fig 1 from Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2− Advanced Breast Cancer
Authors: Bardia Aditya , Modi Shanu , Oliveira Mafalda , Cortes Javier , Campone Mario , Ma Brigette , Dirix Luc , Weise Amy , Hewes Becker , Diaz-Padilla Ivan , Han Yu , Deshpande Priya , Samant Tanay S. , Lorenc Karen Rodriguez , He Wei , Su Fei , Chavez-MacGregor Mariana
Published: April 2023

Supplementary Fig 1
Supplementary Figure 3 from A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations
Authors: Lee Hye Won , Sa Jason K. , Gualberto Antonio , Scholz Catherine , Sung Hyun Hwan , Jeong Byong Chang , Choi Han Yong , Kwon Ghee Young , Park Se Hoon
Published: April 2023

Ampliseq results for the enrolled patients (n = 21)
Supplementary Figure 2 from A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations
Authors: Lee Hye Won , Sa Jason K. , Gualberto Antonio , Scholz Catherine , Sung Hyun Hwan , Jeong Byong Chang , Choi Han Yong , Kwon Ghee Young , Park Se Hoon
Published: April 2023

Comparison of the somatic mutational landscape in our patient population with The Cancer Genome Atlas (TCGA) data
Supplementary Figure 1 from A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations
Authors: Lee Hye Won , Sa Jason K. , Gualberto Antonio , Scholz Catherine , Sung Hyun Hwan , Jeong Byong Chang , Choi Han Yong , Kwon Ghee Young , Park Se Hoon
Published: April 2023

Heatmap showing genomic biomarkers found in all genetically screened patients (n = 224)
Figure S1 from Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study
Authors: Bagley Stephen J. , Nabavizadeh S. Ali , Mays Jazmine J. , Till Jacob E. , Ware Jeffrey B. , Levy Scott , Sarchiapone Whitney , Hussain Jasmin , Prior Timothy , Guiry Samantha , Christensen Theresa , Yee Stephanie S. , Nasrallah MacLean P. , Morrissette Jennifer J.D. , Binder Zev A. , O'Rourke Donald M. , Cucchiara Andrew J. , Brem Steven , Desai Arati S. , Carpenter Erica L.
Published: April 2023

Plasma cell-free DNA (cfDNA) concentration (ng/mL) is correlated with (A), total radiographic tumor burden (contrast-enhancing tumor + T2/FLAIR non-enhancing tumor) and (B), contrast-enhancing tumor burden at the first post-radiation MRI scan in patients with newly diagnosed glioblastoma
Supplementary Figure 4 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Authors: Ladomersky Erik , Zhai Lijie , Lauing Kristen L. , Bell April , Xu Jiahui , Kocherginsky Masha , Zhang Bin , Wu Jennifer D. , Podojil Joseph R. , Platanias Leonidas C. , Mochizuki Aaron Y. , Prins Robert M. , Kumthekar Priya , Raizer Jeffrey J. , Dixit Karan , Lukas Rimas V. , Horbinski Craig , Wei Min , Zhou Changyou , Pawelec Graham , Campisi Judith , Grohmann Ursula , Prendergast George C. , Munn David H. , Wainwright Derek A.
Published: April 2023

Supplemental Figure 4. Confirmatory analysis of T cell depletion method.
Supplementary Figure 3 from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Authors: Ladomersky Erik , Zhai Lijie , Lauing Kristen L. , Bell April , Xu Jiahui , Kocherginsky Masha , Zhang Bin , Wu Jennifer D. , Podojil Joseph R. , Platanias Leonidas C. , Mochizuki Aaron Y. , Prins Robert M. , Kumthekar Priya , Raizer Jeffrey J. , Dixit Karan , Lukas Rimas V. , Horbinski Craig , Wei Min , Zhou Changyou , Pawelec Graham , Campisi Judith , Grohmann Ursula , Prendergast George C. , Munn David H. , Wainwright Derek A.
Published: April 2023

Supplementary Figure 3. Advanced age is associated with decreased overall survival (OS) among both men and women with glioblastoma (GBM).
Supplementary Figure S1 from Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
Authors: Kang Yoon-Koo , Bang Yung-Jue , Kondo Shunsuke , Chung Hyun Cheol , Muro Kei , Dussault Isabelle , Helwig Christoph , Osada Motonobu , Doi Toshihiko
Published: April 2023

Supplementary Figure S1 shows the trial profile.
Table S4 from The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval
Authors: Jordan Kimberly R. , Sikora Matthew J. , Slansky Jill E. , Minic Angela , Richer Jennifer K. , Moroney Marisa R. , Hu Junxiao , Wolsky Rebecca J. , Watson Zachary L. , Yamamoto Tomomi M. , Costello James C. , Clauset Aaron , Behbakht Kian , Kumar T. Rajendra , Bitler Benjamin G.
Published: April 2023

Top 18 genes that correlated with IL6 expression in Nanostring dataset (n=12) and TCGA dataset (n=489).
Supplementary Data from Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma
Authors: Ladomersky Erik , Zhai Lijie , Lauing Kristen L. , Bell April , Xu Jiahui , Kocherginsky Masha , Zhang Bin , Wu Jennifer D. , Podojil Joseph R. , Platanias Leonidas C. , Mochizuki Aaron Y. , Prins Robert M. , Kumthekar Priya , Raizer Jeffrey J. , Dixit Karan , Lukas Rimas V. , Horbinski Craig , Wei Min , Zhou Changyou , Pawelec Graham , Campisi Judith , Grohmann Ursula , Prendergast George C. , Munn David H. , Wainwright Derek A.
Published: April 2023

Supplemental Figure Legends
Table S3 from The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval
Authors: Jordan Kimberly R. , Sikora Matthew J. , Slansky Jill E. , Minic Angela , Richer Jennifer K. , Moroney Marisa R. , Hu Junxiao , Wolsky Rebecca J. , Watson Zachary L. , Yamamoto Tomomi M. , Costello James C. , Clauset Aaron , Behbakht Kian , Kumar T. Rajendra , Bitler Benjamin G.
Published: April 2023

Nanostring transcriptomic data for all genes include on the PanCancer IO 360 Panel and Reverse Protein Phase Array for GTFB 1064 and 1066 (pre and post-NACT).
Table S1 from The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval
Authors: Jordan Kimberly R. , Sikora Matthew J. , Slansky Jill E. , Minic Angela , Richer Jennifer K. , Moroney Marisa R. , Hu Junxiao , Wolsky Rebecca J. , Watson Zachary L. , Yamamoto Tomomi M. , Costello James C. , Clauset Aaron , Behbakht Kian , Kumar T. Rajendra , Bitler Benjamin G.
Published: April 2023

. Histological description of tumors and Cancer antigen 125 (CA125) levels for each patient over time. Units = U/mL
Figure S1 from The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval
Authors: Jordan Kimberly R. , Sikora Matthew J. , Slansky Jill E. , Minic Angela , Richer Jennifer K. , Moroney Marisa R. , Hu Junxiao , Wolsky Rebecca J. , Watson Zachary L. , Yamamoto Tomomi M. , Costello James C. , Clauset Aaron , Behbakht Kian , Kumar T. Rajendra , Bitler Benjamin G.
Published: April 2023

Disease progression for six patients with HGSOC and quality control for transcriptomics
Tables S1 and S2 from Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy
Authors: Zhou Katherine I. , Peterson Bryan , Serritella Anthony , Thomas Joseph , Reizine Natalie , Moya Stephanie , Tan Carol , Wang Yan , Catenacci Daniel V.T.
Published: April 2023

Supplementary Table S1. PD-L1 status by metastatic site. Supplementary Table S2. TMB by metastatic site.
Table S3 from Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy
Authors: Zhou Katherine I. , Peterson Bryan , Serritella Anthony , Thomas Joseph , Reizine Natalie , Moya Stephanie , Tan Carol , Wang Yan , Catenacci Daniel V.T.
Published: April 2023

Supplementary Table S3. Progression-free survival from initiation of ICI therapy among patients with concordant or discordant PD-L1 expression or TMB.
Figure S3 from Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy
Authors: Zhou Katherine I. , Peterson Bryan , Serritella Anthony , Thomas Joseph , Reizine Natalie , Moya Stephanie , Tan Carol , Wang Yan , Catenacci Daniel V.T.
Published: April 2023

Supplementary Figure S3. Comparison of PD-L1 expression before vs. after chemotherapy.
Supplementary Data from NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response
Authors: Swain Sandra M. , Tang Gong , Brauer Heather Ann , Goerlitz David S. , Lucas Peter C. , Robidoux André , Harris Brent T. , Bandos Hanna , Ren Yuqi , Geyer Charles E. , Rastogi Priya , Mamounas Eleftherios P. , Wolmark Norman
Published: April 2023

Tables S1-S6 and Figures S1-S5
Table S1 from Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
Authors: Strosberg Jonathan , Mizuno Nobumasa , Doi Toshihiko , Grande Enrique , Delord Jean-Pierre , Shapira-Frommer Ronnie , Bergsland Emily , Shah Manisha , Fakih Marwan , Takahashi Shunji , Piha-Paul Sarina A. , O'Neil Bert , Thomas Sajeve , Lolkema Martijn P. , Chen Menghui , Ibrahim Nageatte , Norwood Kevin , Hadoux Julien
Published: April 2023

Table S1 lists study sites and investigators who participated in the KEYNOTE-158 NET cohort
Supplementary Legend from CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy
Authors: Xiong Zhengming , Ampudia Mesias Elisabet , Pluhar G. Elizabeth , Rathe Susan K. , Largaespada David A. , Sham Yuk Y. , Moertel Christopher L. , Olin Michael R.
Published: April 2023

Supplementary Legend
Supplementary Data 1 from CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy
Authors: Xiong Zhengming , Ampudia Mesias Elisabet , Pluhar G. Elizabeth , Rathe Susan K. , Largaespada David A. , Sham Yuk Y. , Moertel Christopher L. , Olin Michael R.
Published: April 2023

Generation of Knockout Macrophages (Raw 264.7).
Supplementary Data from FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes
Authors: Sengal Asmerom T. , Patch Ann-Marie , Snell Cameron E. , Smith Deborah S. , Leung Samuel C.Y. , Talhouk Aline , Williams Elizabeth D. , McAlpine Jessica N. , Pollock Pamela M.
Published: April 2023

Supplementary method
Figure S9 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

Blood clearance of i.p.-administered 64Cu-RaftRGD in normal and tumor-bearing mice
Supplementary fig 8 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 8: Changes in immune-related genes in response to NAC are not associated with outcome in ER+ or HER2+ tumors with residual disease.
Figure S8 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

Biodistribution and estimated ADs of i.p.-administered 64Cu-RaftRGD
Figure S7 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

PET quantification and post-PET biodistribution of 64Cu-RaftRGD (OVCAR-3-OCPM mice)
Figure S6 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

PET quantification and post-PET biodistribution of 64Cu-RaftRGD (IGR-OV1-OCPM mice)
Supplementary fig 5 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 5: The change in sTILs during NAC is not prognostic for outcome in TNBC patients with residual disease.
Supplementary fig 2 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 2: Pre-NAC sTILs have minimal prognostic value in breast cancer patients with residual disease.
Supplementary fig 17 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 17: An 8-gene activated T cell signature derived from whole blood at surgery is associated with residual disease burden and recurrence.
Figure S18 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

Reducing effect of Gelofusine and L-lysine on the renal accumulation of 64Cu-RaftRGD
Figure S17 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

Hypoxia levels in OCPMs
Figure S14 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

64Cu-RaftRGD-based TRT (survival study)
Supplementary fig 11 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 11: Cytokine secretion is markedly enriched in PD-1HI T cells after NAC in a patient with pCR to NAC in TNBC.
Supplementary fig 1 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Figure 1: Representative images of high and low sTILs.
Figure S1 from Radiotheranostic Agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer
Authors: Jin Zhao-Hui , Tsuji Atsushi B. , Degardin Mélissa , Sugyo Aya , Obara Satoshi , Wakizaka Hidekatsu , Nagatsu Kotaro , Hu Kuan , Zhang Ming-Rong , Dumy Pascal , Boturyn Didier , Higashi Tatsuya
Published: April 2023

Microscopic examination of ascites
Supplementary Dataset 2 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Dataset 2: Metadata and clonotype data for TCRβ sequencing (Archer) in 4 patients (peripheral CD8+ PD-1HI and CD8+ PD-1NEG T cells and post-NAC tumor), before (n=3) and after (n=4) NAC.
Supplementary Dataset 1 from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Dataset 1: Metadata and clonotype data for TCRβ sequencing (Adaptive) in 15 pairs of NAC-treated patients (tumor data).
Supplementary Data from Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
Authors: Axelrod Margaret L. , Nixon Mellissa J. , Gonzalez-Ericsson Paula I. , Bergman Riley E. , Pilkinton Mark A. , McDonnell Wyatt J. , Sanchez Violeta , Opalenik Susan R. , Loi Sherene , Zhou Jing , Mackay Sean , Rexer Brent N. , Abramson Vandana G. , Jansen Valerie M. , Mallal Simon , Donaldson Joshua , Tolaney Sara M. , Krop Ian E. , Garrido-Castro Ana C. , Marotti Jonathan D. , Shee Kevin , Miller Todd W. , Sanders Melinda E. , Mayer Ingrid A. , Salgado Roberto , Balko Justin M.
Published: April 2023

Supplementary Tables
Supplementary Figure S7 from Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
Authors: Decary Stéphanie , Berne Pierre-François , Nicolazzi Céline , Lefebvre Anne-Marie , Dabdoubi Tarik , Cameron Béatrice , Rival Pierrick , Devaud Catherine , Prades Catherine , Bouchard Hervé , Cassé Alhassan , Henry Christophe , Amara Céline , Brillac Claire , Ferrari Paul , Maçon Laetitia , Lacoste Eric , Combeau Cecile , Beys Eric , Naimi Souad , García-Echeverría Carlos , Mayaux Jean-François , Blanc Véronique
Published: April 2023

Supplementary Figure S7
Supplementary Figure S6 from Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors
Authors: Decary Stéphanie , Berne Pierre-François , Nicolazzi Céline , Lefebvre Anne-Marie , Dabdoubi Tarik , Cameron Béatrice , Rival Pierrick , Devaud Catherine , Prades Catherine , Bouchard Hervé , Cassé Alhassan , Henry Christophe , Amara Céline , Brillac Claire , Ferrari Paul , Maçon Laetitia , Lacoste Eric , Combeau Cecile , Beys Eric , Naimi Souad , García-Echeverría Carlos , Mayaux Jean-François , Blanc Véronique
Published: April 2023

Supplementary Figure S6